Key result
A previously healthy 35-year-old male experienced sudden cardiorespiratory collapse 2 minutes after receiving the Oxford-AstraZeneca COVID-19 vaccine, likely due to underlying coronary artery disease and a vasovagal event.
Why the study?
Due to vast COVID-19 vaccination, fatal adverse events may occur, but sudden cardiorespiratory collapse immediately after vaccination had not been reported.
Case Report (n=1)
No
This case highlights the importance of considering underlying coronary artery disease and performing coronary angiography in patients with out-of-hospital cardiac arrest following COVID-19 vaccination after neurological recovery.
Answers are grounded in this paper and cite their sources.
Supports angiography in post-vaccination arrest after recovery; single case leaves open causality and should not change practice.
Since 2020, new vaccines were developed to fight the coronavirus disease 2019 (COVID-19). Vaccination is important in preventing mortality and achieving herd immunity. However, due to vast vaccination, fatal adverse events could be seen. We report a case of a previously healthy, young male who had a cardiopulmonary arrest 2 min after receiving the Oxford- AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccination. After targeted temperature management, a coronary angiogram was performed after neurological recovery and showed severe stenosis at the proximal left anterior descending artery. Stenting was done and he was discharge. No similar case of sudden cardiorespiratory collapse immediately after COVID-19 vaccination has been reported. Our patient did not have any effort-related angina or dyspnea on exertion before this event. The sudden cardiorespiratory collapse was probably related to underlying coronary artery disease, complicated with a vasovagal event. We stress the importance of coronary angiography in out of hospital cardiac arrest patients after neurological recovery. In the era of COVID-19 vaccination, even though fatal adverse events following immunization are rare, heightened awareness of severe side effects needing medical attention is very important.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2022) conducted a case report in Sudden cardiorespiratory collapse (n=1). Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccine was evaluated on Sudden cardiorespiratory collapse. A previously healthy 35-year-old male experienced sudden cardiorespiratory collapse 2 minutes after receiving the Oxford-AstraZeneca COVID-19 vaccine, likely due to underlying coronary artery disease and a vasovagal event.
Synapse has enriched 10 related papers. Consider them for comparative context: